Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) following the success of a Phase I study. The Phase I trial investigated two single 5,

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are deemed to be at high risk of contracting the human immunodeficiency virus (HIV).